Donor tolerability of convalescent plasma donation

J Clin Apher. 2021 Jun;36(3):429-436. doi: 10.1002/jca.21882. Epub 2021 Feb 15.

Abstract

Background: Since early 2020, convalescent plasma has been widely used for treating coronavirus disease 2019 (COVID-19). There is limited information regarding donor tolerability of convalescent plasma donation. In this study, we evaluated the short-term donor tolerability of convalescent plasma donation.

Methods: A prospective study of 309 convalescent plasma donation related adverse events were conducted at Wuhan Blood Center of China, from February 12 to April 1, 2020. Additionally, up to 28-day post-donation follow-ups were performed on the donors.

Results: Sixteen (5.2%) adverse events were reported in 309 donations. All of these were mild vasovagal without loss of consciousness. The frequency of adverse reactions was higher in donors with a per donation volume of >8 mL/kg body weight or ≥ 600 mL, <100 mm Hg in pre-donation systolic blood pressure, or less than 28 days from the onset of COVID-19 symptoms. There was no correlation to donation history, weight, sex, ABO blood type, pre-donation diastolic blood pressure, pulse, or hemoglobin.

Conclusion: The donation of convalescent plasma is generally safe. Mitigation of risk factors associated with adverse events can further enhance donor tolerability of convalescent plasma donation.

Keywords: adverse donation reaction; convalescent plasma; coronavirus disease 2019.

MeSH terms

  • Adult
  • Blood Donors*
  • COVID-19 / immunology*
  • COVID-19 / therapy*
  • COVID-19 Serotherapy
  • China
  • Convalescence
  • Female
  • Follow-Up Studies
  • Humans
  • Immunization, Passive / methods
  • Male
  • Middle Aged
  • Plasma*
  • Prospective Studies
  • Risk Factors
  • Young Adult